AKT1 and cancer: OA and Asp may inhibit the activation of the NF-κB signaling pathway by inhibiting the expression of AKT and up-regulating the expression of IκBα protein while downregulating the expression of COX2 protein and inhibiting the synthesis of inflammatory transmitters such as prostaglandin (PG) E2, thus reducing the inflammatory reaction and inhibiting the proliferation and survival of cancer cells.